I
iPS PORTAL
A company focused on stem cell research including iPS cells and regenerative medicine research
About iPS PORTAL
iPS Portal is a specialized company offering professional outsourcing services in research and development (R&D), with a strong focus on regenerative medicine, technology, and education. The company serves a diverse range of clients including academic institutions, biotech firms, and pharmaceutical companies. Operating in the highly specialized market of regenerative medicine and advanced technology, iPS Portal provides tailored R&D solutions that help clients accelerate their research and development processes. The business model is service-based, generating revenue through contracts and partnerships for outsourced R&D projects. By leveraging cutting-edge technology and scientific expertise, iPS Portal enables its clients to achieve breakthroughs in medical and technological advancements.
Source: Dealroom company dataAt a glance
- Founded
- 2014
- Headquarters
- Kyoto, Japan
- Sector
- Health
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed14 investors entered at this stage
Ajinomoto
Shin Nippon Biomedical Laboratories (SNBL)
Horiba
Chugai Pharmaceutical
Sumitomo Mitsui Banking
SCREEN Graphic Solutions
Sysmex
Shimadzu- DJDaiichi Jitsugyo
SMBC Venture Capital
Eisai
Daiwa Securities Group
Toyo Seikan
Toho Holdings (Japan)
Series B and later4 investors entered at this stage
NTT
Kataoka- KSKagawa Securities
EXEDY
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about iPS PORTAL on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See iPS PORTAL on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.